ClinicalTrials.Veeva
Menu

Find clinical trials for Melanoma in Paris, Île-de-France

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Non-Small-Cell Lung Carcinoma
Renal Cell Carcinoma
Squamous Cell Carcinoma
Lung Cancer

Melanoma trials near Paris, Île-de-France, FRA:

A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas

of DYP688 as a single agent in patients with metastatic uveal melanoma (MUM) and other melanomas harboring GNAQ/11 mutations....

Enrolling
Metastatic Uveal Melanoma
Drug: DYP688

Phase 1, Phase 2

Novartis
Novartis

Paris, France and 10 other locations

Neoadjuvant/adjuvant IDE196 (darovasertib) in patients with primary uveal melanoma...

Enrolling
Uveal Melanoma
Drug: Darovasertib

Phase 2

Ideaya Biosciences

Paris, France and 24 other locations

ATLAS-IT-05 is an open-label, single-arm study in patients with advanced melanoma accessible for injections (cutaneous, subcutaneous, lymph ...

Active, not recruiting
Advanced Melanoma
Combination Product: LTX-315 in combination with pembrolizumab

Phase 2

Lytix Biopharma

Paris, France and 9 other locations

therapy per local standard of care (SoC), best supportive care (BSC)) on protocol survivor follow up) in patients with advanced non-ocular melanoma...

Enrolling
Advanced Melanoma
Drug: Tebentafusp with Pembrolizumab
Drug: Tebentafusp

Phase 2, Phase 3

Immunocore
Immunocore

Paris, France and 70 other locations

the efficacy and safety of 12 months of encorafenib in combination with binimetinib in adjuvant setting of BRAF V600E/K mutant stage IIB/C melanoma...

Active, not recruiting
Melanoma
Drug: Placebo to match Encorafenib ; Placebo to match Binimetinib
Drug: Encorafenib and Binimetinib

Phase 3

Pierre Fabre
Pierre Fabre

Paris Cedex 10, Paris, France and 154 other locations

(PK) similarity and efficacy, safety, and immunogenicity of ABP 206 compared with OPDIVO® (nivolumab) in subjects with resected advanced melanoma...

Enrolling
Melanoma
Drug: EU-authorized Nivolumab
Drug: ABP 206

Phase 3

Amgen
Amgen

Boulogne Billancourt cedex, Hauts-de-Seine, France and 112 other locations

binimetinib, and pembrolizumab) given together for the treatment of melanoma that:* is advanced or metastatic (spread to other parts of the ...

Active, not recruiting
Melanoma
Drug: Binimetinib
Drug: Encorafenib

Phase 3

Pfizer
Pfizer

Villejuif, France and 227 other locations

the safety of IT BO-112 in combination with intravenous (IV) pembrolizumab. The study will enroll patients with advanced and/or metastatic melanoma...

Active, not recruiting
Melanoma
Procedure: Tissue Biopsies
Drug: BO-112 plus pembrolizumab

Phase 2

Highlight Therapeutics

Paris, France and 18 other locations

of ANV419 with anti-PD1 antibody or with anti-CTLA4 antibody in adult participants with advanced (unresectable or metastatic) cutaneous melanoma...

Enrolling
Melanoma (Skin)
Metastatic Melanoma
Drug: Ipilimumab
Drug: ANV419

Phase 1, Phase 2

Anaveon

Paris, France and 24 other locations

Because we suspect that the benefit of anti-PD-1 in metastatic UM patients could vary according to previous exposure to Tebentafusp (better efficacy...

Enrolling
Metastatic Uveal Melanoma
Drug: Pembrolizumab 25 MG/1 ML Intravenous Solution

Phase 2

Institut Curie

Paris, France

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems